Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Carfilzomib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 20 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Oct 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0694).
- 24 Oct 2013 Planned end date changed from 1 Sep 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov record.